Anorexia nervosa remains one of the deadliest psychiatric disorders, disproportionately affecting young women and marked by severe physical deterioration and complex psychosocial symptoms. Among these symptoms, social impairments including diminished social networks and impaired emotional empathy are pronounced, yet poorly understood on a mechanistic level. Given psilocybin’s serotonergic activity and anti-inflammatory properties, the Monash team sought to dissect how this compound might influence behaviors entwined with serotonin system dysfunction and inflammatory processes, which are implicated across several psychiatric conditions including anorexia.

Prevailing research has largely centered on male subjects, a significant limitation considering the dominant female prevalence of anorexia. Addressing this gap, the researchers utilized female mice subjected to four distinct conditions: a combination of food restriction and voluntary wheel running to simulate ABA, food restriction alone, unlimited food with running wheel access, and standard housing controls. This experimental design enabled a rigorous examination of how metabolic stress, voluntary exercise, and their interactions modulate psilocybin’s behavioral and immunological effects.

Psilocybin was administered when mice in the ABA model reached a critical weight loss threshold, aligning with clinical conditions of anorexia nervosa. The subsequent social preference assays revealed unexpected behavioral profiles—contrary to anticipated social withdrawal, ABA mice demonstrated increased novelty-seeking, favoring novel social partners consistently. This hyperexploratory behavior toward unfamiliar mice was not replicated in food-restricted subjects without exercise, underscoring a fascinating interplay between metabolic challenge and physical activity.

Conversely, mice granted only wheel access without food limitation showed delayed novelty preference emerging during choice tests rather than initial exploration, suggesting that exercise alone primes different social cognitive circuits. Intriguingly, psilocybin administration did not universally enhance sociability but instead inverted typical novelty preferences in control animals, equalizing interactions between familiar and novel partners. In food-restricted, psilocybin-treated mice, a strong correlation emerged between lower body weight and increased motivation toward novel objects rather than social novelty, implying a context-dependent shift potentially linked to heightened food-seeking drives.

Immunological outcomes added further complexity. Contrary to human clinical data indicating elevated inflammatory markers in anorexia, baseline interleukin-6 (IL-6) levels in mouse models did not differ significantly across groups. However, mice with wheel access receiving psilocybin showed a marked elevation in IL-6 compared to all other cohorts, a surprising finding given psychedelics’ traditionally reported anti-inflammatory effects. Even more compelling, this IL-6 increase correlated positively with social novelty preference, hinting at an intricate modulatory axis involving metabolic reward, immune activation, and behavioral output.

These immune-behavior relationships were absent in the ABA and food restriction groups, suggesting that prior metabolic stress blunts or modifies the immune-sensory pathways engaged by psilocybin in exercising animals. The researchers speculate that exercise-induced dopamine pathway activation may create a unique immunometabolic milieu, enabling psilocybin’s divergent effects. The acute timing of sample collection—only hours post-administration—may also capture transient inflammatory responses preceding the longer-term anti-inflammatory benefits documented in human trials.

This meticulous dissection of metabolic, behavioral, and immune parameters challenges simplistic notions of psychedelics as universally beneficial and highlights the necessity of considering individual physiological contexts in therapeutic applications. The absence of expected social deficits in ABA mice, a surprising deviation from clinical symptomatology, points to the limitations of acute or short-term animal models and raises questions about the influence of chronicity, environmental factors, and psychosocial variables unmodeled in rodents.

Clinically, these findings carry profound implications. Psilocybin’s variable effects contingent on exercise and metabolic state hint at biomarkers—such as physical activity patterns or inflammatory status—that could refine patient selection and personalize treatment strategies for anorexia nervosa and related disorders. Additionally, dynamic monitoring of immune markers post-treatment could offer mechanistic insights and prognostic signals for responsiveness, addressing variability observed in current clinical trials where only a subset of participants achieve symptom remission.

Looking forward, the study charts clear avenues for future investigation, advocating for longer duration exposure paradigms mimicking cyclical fasting and refeeding characteristic of chronic anorexia. Temporal profiling of cytokine trajectories and employing a panel of inflammatory and neuroplasticity markers across brain regions will be critical for unraveling the complex temporal and spatial dimensions of psychedelic action. Importantly, a dual-sex investigative strategy is warranted given sex-specific neuropharmacological and behavioral dynamics, a gap this study begins to fill through its exclusive focus on females.

The Monash team’s work exemplifies the power of controlled comparative experimental frameworks in psychedelic research, challenging canonical assumptions and underscoring the profound interplay between neurochemical, immune, and behavioral systems modulated by metabolic context. Their integrative approach, coupling detailed phenotypic assessments with immune profiling, sets a new standard for preclinical investigations and paves the way for translational breakthroughs in the treatment of eating disorders.

Sheida Shadani, who conducted the experiments as part of her doctoral research, alongside Erika Greaves and under the guidance of Professors Zane B. Andrews and Associate Professor Claire Foldi, have contributed an impactful study funded by a National Health and Medical Research Council Ideas Grant. Their findings usher in a new paradigm of personalized psychedelic medicine, emphasizing that understanding the patient’s physiological state—beyond mere diagnosis—may hold the key to unlocking therapeutic efficacy.

This transformative research, freely accessible through the journal Psychedelics as of February 3, 2026, not only advances fundamental science but also invigorates the quest for innovative treatments tailored to the complex neurobiological and immunological realities of disorders like anorexia nervosa. By marrying rigorous methodology with clinical relevance, the study heralds a future where psychedelic therapies are harnessed with precision, maximizing benefit while navigating the subtleties of human physiology.

Subject of Research: Animals

Article Title: Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia

News Publication Date: 3-Feb-2026

Web References: https://doi.org/10.61373/pp026a.0003

Image Credits: Claire J Foldi

Keywords: Psilocybin, Activity-Based Anorexia, Female Mice, Social Behavior, Inflammation, Interleukin-6, Metabolic Stress, Exercise, Novelty-Seeking, Psychedelic Therapy, Eating Disorders, Preclinical Model

The interdisciplinary team utilized sophisticated preclinical models of chronic pain in rodents, including nerve injury-induced and inflammatory pain paradigms, to meticulously analyze the behavioral and neurological effects of psilocybin administration. They demonstrated that a single dose of psilocybin significantly diminishes nociceptive responses as well as anxiety- and depression-like behaviors driven by chronic pain states. Remarkably, these therapeutic effects persisted for nearly two weeks post-administration, suggesting durable neural adaptations. Psilocybin’s pharmacodynamics hinge upon partial agonism of serotonin receptor subtypes 5-HT2A and 5-HT1A, functioning more akin to a modulatory dimmer switch rather than a blunt activator or inhibitor, allowing for refined tuning of serotonergic signaling pathways implicated in both nociception and mood regulation.

To identify the neuroanatomical loci responsible for psilocybin’s effects, investigators administered the active metabolite psilocin via direct microinjections into discrete central nervous system regions. Using high-resolution fluorescent microscopy techniques that visualize real-time neuronal activity through bioluminescent markers, they pinpointed the anterior cingulate cortex (ACC)—a prefrontal brain region integral to the cognitive and emotional processing of pain—as a critical node. Psilocin microinjection into the ACC recapitulated the analgesic and mood-elevating effects observed with systemic administration, whereas spinal cord injections failed to produce comparable relief. This specificity underscores the centrality of top-down cortical modulation over local nociceptive pathways, suggesting psilocybin’s action primarily involves higher-order brain circuitries that integrate sensory and affective dimensions of pain.

This nuanced modulation bypasses peripheral sites of injury, offering a paradigm shift in chronic pain management. Current standard-of-care therapies often rely heavily on opioid analgesics, which pose risks of tolerance, dependency, and adverse side effects. Psilocybin’s unique capacity to alleviate both pain and comorbid affective disturbances without eliciting addictive behaviors positions it as a compelling candidate for safer, multimodal intervention strategies. The dual benefit of symptomatic pain reduction alongside mood enhancement has the potential to disrupt the vicious cycle wherein chronic suffering fuels psychological distress, which in turn amplifies pain perception.

The implications of these findings reach beyond pain medicine. The neural circuits engaged by psilocybin overlap with those implicated in a spectrum of neuropsychiatric disorders characterized by circuit dysregulation, including addiction and post-traumatic stress disorder (PTSD). By fine-tuning dysfunctional circuitry, psilocybin and related psychedelics could revolutionize therapeutic approaches for these conditions, which currently lack robust, broadly effective pharmacotherapies. However, clinical translation requires cautious investigation to establish efficacy, safety, dosing parameters, and the long-term stability of neural reconfiguration induced by psychedelic compounds.

Joseph Cichon, MD, PhD, lead author and assistant professor of Anesthesiology and Critical Care, emphasizes the complex bidirectional relationship between chronic pain and depression commonly encountered in perioperative settings. Surgical trauma can exacerbate both nociceptive and affective symptoms, complicating recovery trajectories. While psilocybin’s demonstrated effects hold promise for addressing both facets simultaneously, the unique physiological and psychological stresses imposed by surgery mandate rigorous clinical trials to ascertain the suitability of psychedelic-assisted interventions in these contexts. Moreover, anesthesiology practice involves delicate neuropharmacological balancing, underscoring the need for integrated protocols rooted in mechanistic understanding.

Further research led by Stephen Wisser, a PhD neuroscience candidate in Dr. Cichon’s laboratory, aims to elucidate the optimal dosing regimens, frequency of administration, and the molecular underpinnings of neuroplastic changes sustained after psilocybin exposure. Given the observed prolonged behavioral improvements in animal models, understanding the capacity of the brain’s pain and mood circuits to rewire provides fundamental insights into how psychedelics may provide enduring relief rather than transient symptomatic palliation. This work could lead to development of targeted interventions that harness endogenous neuroplasticity, maximizing therapeutic gain while minimizing exposure.

The study’s robust experimental design combined state-of-the-art techniques, including fluorescent calcium imaging and region-specific receptor modulation, to validate hypotheses on receptor-specific activation and downstream circuit engagement. The findings highlight the anterior cingulate cortex’s pivotal role in gating both sensory input and emotional valuation of pain—a duality often overlooked in traditional analgesic strategies that focus solely on nociceptive transmission. This integrative approach aligns with emerging paradigms viewing chronic pain as a multidimensional phenomenon requiring circuit-based therapeutic targeting.

Funding from the National Institutes of Health and the American Society of Regional Anesthesia and Pain Medicine attests to the critical relevance of this research. As the healthcare community grapples with the ongoing opioid crisis and the limitations of existing pain management modalities, psychedelics such as psilocybin offer a beacon of hope. Their historical stigmatization is slowly being replaced by rigorous scientific inquiry revealing multifaceted neurobiological mechanisms and therapeutic potential.

Penn Medicine’s multidisciplinary team exemplifies the forefront of neuroscience and anesthesiology collaboration, driving innovation that bridges molecular pharmacology and clinical pain treatment. Their pioneering work contributes to an evolving narrative that psychedelic compounds, once relegated to fringe status, might soon integrate into mainstream medicine as transformative tools for chronic pain and mental health.

In summary, this landmark research elucidates how psilocybin modulates key brain circuits involved in pain and mood regulation, particularly emphasizing the anterior cingulate cortex’s role in integrating these complex processes. By leveraging advanced neuroimaging and animal behavioral models, the investigators provide compelling evidence that psilocybin’s unique receptor interactions enact durable improvements in both sensory and affective dimensions of pain. These insights pave the way for novel non-addictive therapies capable of breaking the chronic pain-depression cycle that plagues millions worldwide, underscoring psychedelics’ resurgence as potent neurotherapeutics.

Subject of Research: Neural mechanisms of psilocybin in chronic pain and mood regulation

Article Title: Penn Medicine Researchers Identify Brain Circuits Targeted by Psilocybin to Alleviate Chronic Pain and Comorbid Depression

News Publication Date: 2024

Web References:

• University of Pennsylvania Perelman School of Medicine
• Nature Neuroscience

Keywords: Psilocybin, chronic pain, depression, anterior cingulate cortex, serotonin receptors, 5-HT2A, 5-HT1A, neuroplasticity, pain modulation, psychedelics, non-opioid analgesics, mental health, neuroscience